GWPH Q1 2017 Losses Less Than Expected

Canna-pharma giant, GW Pharmaceuticals, posted a Q1 2017 loss of $2.54 million. This is an improvement from the same period in 2016 where the company announced a $4.53 million loss. GWPH is banking on their lead cannabinoid product, Epidiolex. The company is also planning to introduce a candidate for autism spectrum disorders, which could be very exciting for the company.